As of 2025-09-18, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -7.63 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 23.09 USD, the upside of Viking Therapeutics Inc is -133.04%.
Based on its market price of 23.09 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 133.04%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.63 - -7.63 | -7.63 | -133.04% |
| P/E | (16.97) - (23.77) | (21.13) | -191.5% |
| DDM - Stable | (9.72) - (35.23) | (22.47) | -197.3% |
| DDM - Multi | (0.60) - (1.73) | (0.89) | -103.9% |
| Market Cap (mil) | 2,596.24 |
| Beta | 1.28 |
| Outstanding shares (mil) | 112.44 |
| Enterprise Value (mil) | 2,562.36 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.45% |
| Cost of Debt | 5.00% |
| WACC | 7.56% |